Chronic Bronchitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Chronic bronchitis is a chronic obstructive pulmonary disease (COPD) characterized by a productive cough lasting over 3 months within 2 years. Commonly, patients exhibit persistent productive cough, malaise, and excessive coughing-related symptoms such as chest or abdominal pain. The leading cause of chronic bronchitis is exposure to cigarette smoke through active smoking or passive inhalation. Other respiratory irritants like smog, industrial pollutants, and toxic chemicals can also trigger it. While bacterial or viral infections typically cause acute bronchitis, repeated exposure can lead to the chronic form. Influenza types A and B, Staphylococcus, Streptococcus, and Mycoplasma pneumonia are predominant causative agents. Individuals with a history of respiratory conditions like asthma, cystic fibrosis, or bronchiectasis are more susceptible, as are those exposed to environmental pollutants like dust or airborne chemicals, including ammonia and sulfur dioxide. Chronic gastroesophageal reflux is a less common but documented cause. A hallmark symptom of chronic bronchitis is persistent coughing. The defining cough pattern includes its presence on most days for 3 months, occurring at least 2 times annually for 2 consecutive years. About 50% of patients experience productive coughs with sputum. Chronic bronchitis is believed to result from excessive mucus production by goblet cells due to overstimulation. Epithelial cells lining the airways release inflammatory mediators in response to harmful stimuli, contributing to the condition—regulatory substances such as angiotensin-converting enzymes and neutral endopeptidase decrease in release. The alveolar epithelium both triggers and is affected by the inflammatory process. During exacerbations, the bronchial mucous membrane becomes swollen and hyperemic, reducing mucociliary function. Pharmacological treatments consist of:
- Bronchodilators: Short and long-acting β-adrenergic agonists and anticholinergics increase airway lumen, ciliary function, and mucous hydration.
- Glucocorticoids: These reduce inflammation and mucus production. Inhaled corticosteroids enhance quality of life and reduce exacerbations but require careful use due to potential side effects.
- Antibiotics: Generally not used for chronic bronchitis, but macrolides with anti-inflammatory properties might be considered.
- Phosphodiesterase-4 inhibitors decrease inflammation and induce airway smooth muscle relaxation by preventing cyclic adenosine monophosphate degradation.
Chronic bronchitis leads to worsened airflow obstruction, declining lung function, and increased COPD risk. It heightens mortality and is associated with elevated serum IL8 and C-reactive protein levels, suggesting links to cardiac issues and other comorbidities. Quality of life is also significantly diminished by chronic bronchitis.
Thelansis’s “Chronic Bronchitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Bronchitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Chronic Bronchitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Bronchitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment